Earnings calls

Alkem Laboratories concalls

Every Alkem Laboratories earnings call we streamed: the live audio and our summary of what management said.

NSE: ALKEMISIN INE540L01014

Calls

Thu, 12 Nov 4:30 PM

Alkem Laboratories

ALKEMQ2 FY27 earnings call

Q2 FY27 revenue ₹4,520 Cr (+13.8%) and EBITDA margin 22.5%, but PAT fell 11.7%. US constant-currency sales contracted 3% on price erosion.

Summary ready

Q2 FY27: key takeaways

Call page →

Q2 FY27 revenue ₹4,520 Cr (+13.8%) and EBITDA margin 22.5%, but PAT fell 11.7%. US constant-currency sales contracted 3% on price erosion.

Outlook

FY27 US growth mid-single-digit in constant currency; margin near FY26's 20.4%. Enzene ₹300–350 Cr, MedTech ~₹400 Cr capex over 3–4 years.

Earlier call summaries

All →

1 Jun 2026 16:27 IST BSE

Earnings Call

Alkem Laboratories Earnings Call: Key Takeaways

Alkem reported strong FY26 results with landmark INR 3,000cr+ EBITDA. Strategy focuses on chronic therapy growth in India and international expansion, particularly with the semaglutide launch.

Open call summary → Read the filing ↗

Alkem Laboratories Ltd: key numbers

Share price: ₹5,114.00
Market cap: ₹61,146 Cr
Revenue (annual): ₹14,712 Cr
Net profit (annual): ₹2,302 Cr
P/E (TTM): 29.6×Sector 43.7×
Promoter holding: 49.70%+0.00% QoQ
FII holding: 10.32%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.